Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for GLP-1 and other peptide candidates remains active following the December 2025 extension of their original October 2024 agreement through the October 7, 2026 deadline. This extension reflects continued in-vivo studies but also underscores timeline slippage, as the initial 14-month window has stretched toward 24 months without a commercial licensing or technology-transfer deal. Lilly’s June 2025 licensing of Camurus’ competing FluidCrystal technology and its accelerated push into oral obesity candidates like orforglipron have introduced alternative delivery options, creating uncertainty about whether SmartDepot will secure broader rights. Traders see the narrow 54% probability for “No” as reflecting these competing priorities and lack of confirmed progress, with potential tipping points including final study readouts or any official statements on technology transfer before the October cutoff.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
NOWE
NOWE
Oct 7, 2026
NOWE
NOWE
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for GLP-1 and other peptide candidates remains active following the December 2025 extension of their original October 2024 agreement through the October 7, 2026 deadline. This extension reflects continued in-vivo studies but also underscores timeline slippage, as the initial 14-month window has stretched toward 24 months without a commercial licensing or technology-transfer deal. Lilly’s June 2025 licensing of Camurus’ competing FluidCrystal technology and its accelerated push into oral obesity candidates like orforglipron have introduced alternative delivery options, creating uncertainty about whether SmartDepot will secure broader rights. Traders see the narrow 54% probability for “No” as reflecting these competing priorities and lack of confirmed progress, with potential tipping points including final study readouts or any official statements on technology transfer before the October cutoff.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 5, 2026, 8:02 PM ET
Wolumen
$8,217Data zakończenia
Oct 7, 2026Rynek otwarty
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for GLP-1 and other peptide candidates remains active following the December 2025 extension of their original October 2024 agreement through the October 7, 2026 deadline. This extension reflects continued in-vivo studies but also underscores timeline slippage, as the initial 14-month window has stretched toward 24 months without a commercial licensing or technology-transfer deal. Lilly’s June 2025 licensing of Camurus’ competing FluidCrystal technology and its accelerated push into oral obesity candidates like orforglipron have introduced alternative delivery options, creating uncertainty about whether SmartDepot will secure broader rights. Traders see the narrow 54% probability for “No” as reflecting these competing priorities and lack of confirmed progress, with potential tipping points including final study readouts or any official statements on technology transfer before the October cutoff.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Wolumen
$8,217Data zakończenia
Oct 7, 2026Rynek otwarty
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing evaluation of Peptron’s SmartDepot sustained-release microsphere platform for GLP-1 and other peptide candidates remains active following the December 2025 extension of their original October 2024 agreement through the October 7, 2026 deadline. This extension reflects continued in-vivo studies but also underscores timeline slippage, as the initial 14-month window has stretched toward 24 months without a commercial licensing or technology-transfer deal. Lilly’s June 2025 licensing of Camurus’ competing FluidCrystal technology and its accelerated push into oral obesity candidates like orforglipron have introduced alternative delivery options, creating uncertainty about whether SmartDepot will secure broader rights. Traders see the narrow 54% probability for “No” as reflecting these competing priorities and lack of confirmed progress, with potential tipping points including final study readouts or any official statements on technology transfer before the October cutoff.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania